7,837 Shares in Stryker Corporation $SYK Bought by United Services Automobile Association

Key Points

• United Services Automobile Association acquired 7,837 shares of Stryker Corporation, valued at approximately $2.86 million, in the first quarter of this year.
• Stryker's shares saw a price increase forecast by analysts, with targets set between $415 to $455, and a consensus rating of Moderate Buy from 15 analysts.
• The company recently announced a quarterly dividend of $0.84 per share, contributing to an annual yield of 0.9%, with a dividend payout ratio of 44.50%.

United Services Automobile Association purchased a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,837 shares of the medical technology company's stock, valued at approximately $2,857,000.

Other large investors have also recently added to or reduced their stakes in the company. Capital A Wealth Management LLC purchased a new stake in Stryker in the 4th quarter valued at approximately $26,000. Goodman Advisory Group LLC acquired a new stake in shares of Stryker during the first quarter valued at $32,000. City Holding Co. increased its position in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Stryker in the 1st quarter valued at about $40,000. Finally, Cornerstone Planning Group LLC lifted its holdings in Stryker by 46.0% in the 1st quarter. Cornerstone Planning Group LLC now owns 127 shares of the medical technology company's stock valued at $45,000 after purchasing an additional 40 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC boosted their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Citigroup reiterated a "buy" rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Wells Fargo & Company raised their price target on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a "hold" rating in a research note on Monday, August 4th. Finally, BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Stock Down 0.6%

Shares of Stryker stock opened at $392.02 on Monday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $149.87 billion, a price-to-earnings ratio of 51.92, a price-to-earnings-growth ratio of 2.85 and a beta of 0.93. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average price of $389.52 and a 200 day moving average price of $379.51.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter in the previous year, the firm posted $2.81 earnings per share. The firm's quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.